Log In
Print this Print this

oral rolapitant (Varubi) (SCH 619734)

  Manage Alerts
Collapse Summary General Information
Company Opko Health Inc.
DescriptionNeurokinin 1 (NK1) substance P receptor (TACR1) antagonist
Molecular Target Neurokinin 1 (NK1) substance P receptor (TACR1)
Mechanism of ActionNeurokinin-1 (NK-1) (Substance P) receptor antagonist
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentApproved
Standard IndicationEmesis
Indication DetailsPrevent chemotherapy-induced nausea and vomiting (CINV); Treat post-operative nausea and vomiting (PONV)
Regulatory Designation
Partner Jiangsu Hengrui Medicine Co. Ltd.; Tesaro Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments





 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today